|
Oncomatryx Biopharma S. L. is a pharmaceutical biotechnology company that develops personalized treatments against invasive cancer as well as tests for its early detection. Established by Laureano Simón, PhD, Oncomatryx thus engages twofold in the fight against invasive kinds of cancer, such as pancreatic cancer or invasive breast cancer, all of which have high mortality rates. Oncomatryx's research focuses on peritumoral stroma, which has been found to take part in promoting cancer invasiveness and curtailing treatment efficacy.〔 〕 == Laureano Simón == Laureano Simón began his business career in 2000 with the creation of Progenika Biopharma S.A., a personalized medicine company which was acquired by Grifols in February 2013.〔(Biospace.com )〕 Dr. Simón holds a Ph.D. in Chemical Sciences (Molecular Biology) by the Universidad Autónoma de Madrid, a Master’s degree in Biotechnology by the University of Navarra, an MSc by the “University of Wisconsin-Madison” and a Bachelor’s degree in Pharmacy by the University of Santiago de Compostela. He has patented, among others, clinical products such as BLOODchip and LIPOchip. He has also published many articles in scientific journals and has received several awards throughout his career, among which it is worth noting European Eurowards Entrepreneurship Award in 2004, Ernst & Young’s Most Innovative Entrepreneur of the Year in 2010 and (Ruban D´Honneur of the European Business Awards ) -HSBC Bank in 2011. He has participated in science and technology development plans from both the Spanish and the Basque Governments and has contributed to several private foundations, like the Carlos Slim Institute of Health, the Fundación Pedro Barrié de la Maza and the BBVA Foundation. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Oncomatryx」の詳細全文を読む スポンサード リンク
|